Rollover Study of VX-770 in Cystic Fibrosis Subjects
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study was to evaluate the safety of long-term VX-770 treatment
in participants with cystic fibrosis (CF). The secondary objective of the study was to
evaluate the efficacy of long-term VX-770 treatment in subjects with CF.
Phase:
Phase 3
Details
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics